List of Excipients in Branded Drug CLONAZEPAM

Generic Drugs Containing CLONAZEPAM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	clonazepam	0093-0832	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	clonazepam	0093-0832	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	clonazepam	0093-0832	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	clonazepam	0093-0832	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	clonazepam	0093-0832	POVIDONE K90
Teva Pharmaceuticals USA Inc	clonazepam	0093-0832	STARCH, CORN
Teva Pharmaceuticals USA Inc	clonazepam	0093-9290	ASPARTAME

What are the Most Frequently-Used Excipients in CLONAZEPAM?

# Of NDCs	Excipient
3	ALUMINUM OXIDE
63	ANHYDROUS LACTOSE
10	ASPARTAME
174	CELLULOSE, MICROCRYSTALLINE
64	CROSCARMELLOSE SODIUM
10	CROSPOVIDONE
15	D&C RED NO. 30

Clonazepam Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 5, 2026

Clonazepam is a mature, genericized benzodiazepine with limited composition-of-matter protection and substantial price competition in conventional tablets. Commercial opportunity is concentrated in differentiated delivery systems, excipient-led tolerability improvements, pediatric and geriatric formats, and manufacturing efficiencies. The strongest near-term concepts are orally disintegrating tablets, low-volume liquid products, lactose-free formulations, and unit-dose products for institutional use.

What is the commercial status of clonazepam?

Clonazepam is a long-acting benzodiazepine marketed originally as Klonopin by Roche and now supplied primarily through generic manufacturers. It is approved for seizure disorders and panic disorder in the United States. The drug is a Schedule IV controlled substance under the federal Controlled Substances Act and carries class-wide benzodiazepine risks involving abuse, misuse, addiction, physical dependence, and withdrawal reactions (FDA, 2020; DEA, n.d.).

Attribute	Clonazepam
Active ingredient	Clonazepam
Therapeutic class	Benzodiazepine anticonvulsant and anxiolytic
Common strengths	0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg
Common dosage forms	Immediate-release tablets and orally disintegrating tablets
Original brand	Klonopin
U.S. regulatory pathway	NDA for originator; ANDA for most generics
Controlled-substance schedule	Schedule IV
Biosimilar exposure	None; clonazepam is a small molecule
Patent position	Core composition and early product protection expired
Main commercial constraint	Generic price erosion and controlled-substance compliance

Clonazepam has been available in generic form for decades. The conventional tablet market is therefore a scale business. Manufacturing cost, supply reliability, state-level controlled-substance compliance, and wholesaler access are more important than broad patent exclusivity.

What patents protect clonazepam products?

The original clonazepam composition-of-matter and product patents are expired, removing the principal barrier to generic entry. Current commercial protection is more likely to arise from formulation patents, method-of-use claims, manufacturing processes, trademarks, and regulatory exclusivities associated with a new product format.

What is the Orange Book status of Klonopin?

Klonopin is an established product, and generic clonazepam products have been approved through the ANDA pathway. The Orange Book historically has not provided a meaningful unexpired patent barrier for standard clonazepam tablets. Any launch assessment should distinguish between:

1. The reference product’s historical patents.
2. Active patents listed against a specific NDA or dosage form.
3. Patent claims held by third parties but not listed in the Orange Book.
4. Process and trade-secret protections that do not block an ANDA but can complicate manufacturing.

An ANDA applicant seeking approval for a listed product may use Paragraph I, II, III, or IV certifications under the Hatch-Waxman framework. For a mature clonazepam tablet, a Paragraph IV challenge is generally less commercially important than bioequivalence, controlled-substance compliance, supply economics, and potential formulation differentiation.

Can new clonazepam excipients support patent protection?

Yes, but the excipient itself will rarely create meaningful protection. A patentable position would generally require a technically supported combination involving:

• A defined clonazepam particle-size distribution.
• A specific dissolution or disintegration profile.
• A taste-masking system.
• A low-dose content-uniformity solution.
• A preservative and pH system for liquid dosage forms.
• A moisture-control architecture for orally disintegrating tablets.
• A manufacturing process that produces a reproducible critical quality attribute.
• A clinically relevant reduction in administration burden or excipient-related intolerance.

A claim covering only clonazepam plus a conventional diluent, binder, lubricant, or sweetener would face substantial obviousness risk. Stronger claims would link the excipient system to measurable performance, such as rapid disintegration without friability failure, improved dissolution under discriminatory conditions, or stability through the labeled shelf life.

Which excipients are used in clonazepam products?

Excipient composition varies by manufacturer and dosage form. Conventional clonazepam tablets commonly use lactose, microcrystalline cellulose, corn starch, and magnesium stearate, with colorants in selected strengths. Orally disintegrating products can use mannitol, gelatin or other matrix-forming materials, superdisintegrants, sweeteners, flavors, and lubrication systems. The exact formulation must be taken from the applicable product label and approved regulatory filing (DailyMed, n.d.-a; DailyMed, n.d.-b).

Formulation objective	Suitable excipient categories	Key technical issue
Tablet dilution and compressibility	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Low-dose content uniformity
Rapid disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Mechanical strength versus disintegration
ODT mouthfeel	Mannitol, xylitol, co-processed excipients	Cooling effect, sweetness, friability
Taste masking	Flavors, ion-exchange resins, cyclodextrins, polymer coatings	Dose release and sensory performance
Lubrication	Magnesium stearate, sodium stearyl fumarate	Dissolution and over-lubrication
Liquid suspension	Suspending agents, wetting agents, buffers	Sedimentation, redispersibility, dose accuracy
Preserved liquid	Approved antimicrobial preservatives and buffers	Preservative efficacy and pediatric acceptability
Moisture control	Desiccants, high-barrier packaging, low-moisture excipients	ODT stability and packaging cost

Clonazepam is administered at low doses, making blend uniformity a central development issue. Segregation can occur when the active pharmaceutical ingredient has a different particle size, density, or electrostatic profile from the excipient blend. Ordered mixing, geometric dilution, API particle engineering, or spray-dried intermediate systems can improve content uniformity.

What excipient strategy is best for clonazepam orally disintegrating tablets?

The most commercially attractive formulation strategy is a robust ODT designed for patients who have difficulty swallowing conventional tablets. Clonazepam ODT products already exist, so a new product would need measurable advantages rather than a simple dosage-form change.

ODT development priorities

A differentiated clonazepam ODT should target:

• Disintegration in approximately 30 seconds or less under an appropriate validated method.
• Low friability despite rapid breakup.
• Acceptable taste without delaying dissolution.
• Reduced sensitivity to humidity.
• Adequate dose uniformity at 0.125 mg and 0.25 mg strengths.
• Packaging that supports pharmacy handling and patient portability.
• No need for water during administration.

Mannitol is commercially useful because it provides a relatively clean mouthfeel and can support direct compression. Crospovidone or croscarmellose sodium can improve tablet breakup, but excessive superdisintegrant loading may reduce tablet strength. Magnesium stearate can impair wetting and dissolution when used at excessive levels or with prolonged lubrication.

Taste masking requires particular care because clonazepam is pharmacologically potent and may create a bitter or unpleasant oral sensation even at low dose. Polymer coating, ion-exchange resin complexation, cyclodextrin inclusion, or flavor systems can be evaluated. The formulation must release clonazepam rapidly after swallowing while limiting release in the mouth.

Aspartame or other sweeteners may create labeling and patient-population considerations. A sugar-free, aspartame-free ODT could target patients with phenylketonuria, diabetes, or excipient sensitivities, but the commercial benefit must be balanced against taste performance and cost.

What liquid formulation opportunities exist for clonazepam?

Clonazepam is poorly water soluble, which makes a true aqueous solution technically more difficult than a suspension or cosolvent-based liquid. A liquid product can still create commercial value for pediatric, geriatric, enteral-tube, and dysphagia populations.

Suspension versus solution

A clonazepam oral suspension would require control of:

• Particle-size distribution.
• Sedimentation rate.
• Redispersibility.
• Dose withdrawal accuracy.
• Container adsorption.
• Preservative efficacy.
• Chemical and physical stability.
• Uniformity throughout the in-use period.

A cosolvent or surfactant system may improve apparent solubility but can create safety and tolerability concerns, particularly in pediatric patients. Ethanol and propylene glycol require careful evaluation because of age-related and cumulative exposure considerations. A preservative-free multidose system could command a premium but would require an appropriate microbial-control strategy, such as unit-dose packaging or validated container-closure protection.

An oral suspension with a calibrated oral syringe may have stronger practical value than a conventional bottle-and-spoon system. A unit-dose, ready-to-administer liquid could also address institutional dispensing and controlled-substance accountability.

Which excipient-led commercial opportunities are strongest?

Opportunity	Target population	Differentiation	Commercial potential
Premium ODT	Dysphagia, geriatric, psychiatric, seizure patients	Water-free administration and taste control	Moderate
Low-dose ODT	Pediatric or titration use	0.125 mg and 0.25 mg accuracy	Moderate to high
Lactose-free tablet	Patients with lactose intolerance or excipient preference	Simple label differentiation	Low to moderate
Aspartame-free ODT	Patients with phenylketonuria or sweetener concerns	Label and patient-segment differentiation	Low to moderate
Oral suspension	Pediatric, geriatric, feeding-tube use	Flexible dosing and administration	Moderate
Unit-dose liquid	Hospitals, long-term care, specialty pharmacies	Controlled-substance workflow	Moderate
High-barrier ODT packaging	Humid markets and institutional supply	Shelf-life and handling performance	Moderate
Co-processed direct-compression tablet	Generic manufacturers	Lower manufacturing cost and better uniformity	Moderate

The strongest opportunity is not a new excipient claim by itself. It is an integrated product comprising a dosage form, validated administration device, controlled-substance distribution model, and regulatory position that supports a differentiated price.

What FDA regulatory pathway applies to new clonazepam formulations?

A conventional generic tablet or ODT that is therapeutically equivalent to the reference product would generally use an ANDA. A materially different dosage form, route, strength, or formulation may require a 505(b)(2) application, depending on the product design and the extent of reliance on FDA’s prior findings for clonazepam.

Key FDA issues include:

• Demonstration of bioequivalence where applicable.
• Comparative dissolution and disintegration.
• Content uniformity at low strengths.
• Stability under ICH conditions.
• Extractables and leachables for liquid products.
• Preservative efficacy for multidose liquids.
• Human factors for oral syringes or unit-dose systems.
• Controlled-substance security and distribution controls.
• Abuse, misuse, and withdrawal labeling consistent with benzodiazepine class requirements.

A new ODT does not automatically receive a new period of market exclusivity. Patent protection must arise from patentable formulation, manufacturing, or use claims. Regulatory approval alone does not prevent generic competition once the applicable legal requirements are met.

What manufacturing and intellectual-property barriers affect clonazepam?

The main manufacturing barriers are operational rather than fundamental chemistry barriers.

Manufacturing risks

Low-dose clonazepam products require validated controls for:

• Potent-API containment.
• Blend uniformity.
• Cross-contamination prevention.
• Cleaning validation.
• Tablet weight variation.
• Dust control.
• Moisture protection.
• Serialization and controlled-substance inventory reconciliation.

For ODTs, humidity can compromise mechanical strength and disintegration. For suspensions, physical instability can create dose nonuniformity. These risks can support trade-secret protection around process parameters, but trade secrets do not provide the same exclusionary power as a valid patent.

Patent opportunities

Potential patent families could cover:

1. Clonazepam particles with a defined size or morphology.
2. A taste-masked clonazepam complex.
3. A high-load or low-dose co-processed excipient.
4. A moisture-resistant ODT.
5. A preservative-free unit-dose suspension.
6. A container-closure system that maintains stability.
7. A dosing device integrated with a liquid formulation.
8. A method for improving administration adherence in a defined patient group.

Patent strength would depend on comparative data against existing clonazepam tablets and ODTs. A formulation that only reproduces the performance of an established product would face a weaker inventive-step position.

Which companies are challenging clonazepam exclusivity?

Clonazepam is already a heavily genericized product. Competition comes from multiple ANDA holders rather than a small number of identifiable Paragraph IV challengers. Generic manufacturers commonly compete through:

• Tablet and ODT availability.
• National wholesaler contracts.
• Controlled-substance quota management.
• Reliable supply during shortages.
• Low acquisition cost.
• Multiple strength coverage.
• Contract manufacturing and private-label supply.

No biosimilar pathway applies because clonazepam is not a biologic. Licensing opportunities are more likely to involve a specialty generic company, a formulation developer, a contract development and manufacturing organization, or a regional distributor than an originator-led biologics arrangement.

How does clonazepam compare with competing benzodiazepine products?

Product	Main differentiated attribute	Excipient opportunity
Clonazepam	Long duration and seizure/panic indications	ODT, low-dose titration, liquid administration
Lorazepam	Shorter duration and injectable availability	Sublingual and injectable delivery
Diazepam	Multiple dosage forms, including rectal and nasal products	Nasal-device and pediatric formulations
Alprazolam	High-volume anxiety market	ODT and immediate-release tablet competition
Midazolam	Rapid onset and parenteral/intranasal use	Device-led delivery and unit-dose products

Clonazepam is less attractive for a broad commodity launch than high-volume alprazolam, but it may offer a defensible niche in dysphagia, seizure management, pediatric dosing, and institutional administration.

What generic launch risks exist for a new clonazepam product?

A new entrant faces five principal risks:

1. Price compression. Conventional tablets have limited room for premium pricing.
2. Substitution. Pharmacies may substitute among therapeutically equivalent products.
3. Controlled-substance supply limits. Manufacturing quotas and compliance controls can constrain growth.
4. Clinical differentiation risk. Patients and prescribers may not switch from established generics without a clear administration benefit.
5. Patent weakness. Narrow excipient patents may not prevent design-around products.

A viable launch should prioritize a specific unmet administration problem, secure reliable supply, and use packaging or dosing devices as part of the commercial product rather than relying solely on a novel excipient.

What is the revenue exposure for clonazepam manufacturers?

Revenue exposure is concentrated in unit volume rather than sustained exclusivity. Standard tablet sales are vulnerable to:

• Additional ANDA entrants.
• Pharmacy purchasing consolidation.
• Reimbursement pressure.
• Wholesaler inventory decisions.
• Product discontinuations and shortages.
• State and federal controlled-substance scrutiny.

A differentiated ODT or liquid product can improve gross margin if it captures a specialty segment, but market size is smaller than the total generic tablet market. Institutional and specialty-pharmacy contracts can support predictable volume, while retail premium pricing is harder to maintain.

Key Takeaways

• Clonazepam is a mature generic small molecule with no biosimilar pathway and limited value in conventional tablet patenting.
• The strongest commercial opportunities involve ODTs, low-dose titration, oral suspensions, unit-dose liquids, and lactose- or aspartame-free formulations.
• Excipient selection must address low-dose uniformity, poor water solubility, taste, moisture sensitivity, and controlled-substance manufacturing.
• A new formulation may use an ANDA or 505(b)(2) pathway depending on dosage-form and reliance characteristics.
• Patent value will depend on comparative performance data, not the use of routine excipients.
• Trade secrets, process control, packaging, and supply reliability may provide more practical commercial protection than narrow formulation patents.
• The most defensible product concept is an integrated dosage form and administration system aimed at dysphagia, pediatric dosing, geriatric use, or institutional dispensing.

FAQs

Can clonazepam be formulated as a water-soluble oral solution?

Clonazepam has poor water solubility. A stable liquid may require suspension technology, cosolvents, surfactants, complexation, or another solubilization approach. Physical stability and dose uniformity are central development risks.

Is a clonazepam orally disintegrating tablet patentable?

An ODT may be patentable if it has a non-obvious excipient system or measurable performance advantage, such as improved taste masking, moisture resistance, low-dose uniformity, or rapid disintegration with adequate tablet strength.

Which clonazepam strength is most difficult to formulate?

The 0.125 mg and 0.25 mg strengths present the greatest content-uniformity challenge because the API load is very low relative to the excipient mass.

Can a new clonazepam formulation receive market exclusivity?

Approval does not automatically create exclusivity. Exclusivity may arise from an applicable statutory provision, while commercial protection may come from valid formulation, manufacturing, device, or method-of-use patents.

Is clonazepam appropriate for an over-the-counter formulation?

No. Clonazepam is a controlled prescription benzodiazepine with substantial abuse, dependence, withdrawal, and safety risks. An OTC strategy would face significant regulatory and clinical barriers.

References

DailyMed. (n.d.-a). Klonopin clonazepam tablet: Prescribing information. U.S. National Library of Medicine.

DailyMed. (n.d.-b). Clonazepam orally disintegrating tablet: Prescribing information. U.S. National Library of Medicine.

Drug Enforcement Administration. (n.d.). Drug scheduling. U.S. Department of Justice.

U.S. Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. https://www.fda.gov

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (n.d.). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.